Swiss National Bank
PRLD icon

Swiss National Bank’s Prelude Therapeutics PRLD Stock Holding History

Swiss National Bank’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-29,700
Closed -$205K – 2780
2022
Q1 		$205K Buy
29,700
+2,200
+8% +$20.1K ﹤0.01% 2676
2021
Q4 		$342K Buy
27,500
+7,000
+34% +$114K ﹤0.01% 2708
2021
Q3 		$641K Hold
20,500
– – ﹤0.01% 2542
2021
Q2 		$587K Buy
+20,500
New +$730K ﹤0.01% 2608

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Swiss National Bank's PRLD Position: Q2 2022 in Review

Swiss National Bank sold out of Prelude Therapeutics (PRLD) in Q2 2022, closing a stake of 29,700 shares — an estimated $205K sold.

Swiss National Bank first reported a position in PRLD in Q2 2021 and held it in 4 quarters. The position peaked at $641K in Q3 2021. 62 funds tracked by Wall St. Rank hold PRLD as of Q2 2022.

  • Swiss National Bank reported no remaining Prelude Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Swiss National Bank sold 29,700 Prelude Therapeutics shares in Q2 2022, an estimated $205K.
  • Swiss National Bank first reported a position in Prelude Therapeutics in Q2 2021 and held it in 4 quarters.
  • Swiss National Bank's Prelude Therapeutics position peaked at $641K in Q3 2021.
  • 62 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2022.

Based on Swiss National Bank's 13F filing for Q2 2022, filed 9 Aug 2022.